ZEALAND PHARMA
-
Zealand Pharma seeks big pharma partners for obesity drug candidate
"The reason that we need a big pharma partner along us at one point is to secure global reach but it's also because of investments into manufacturing," CEO Adam Steensberg told Reuters after the company reported second-quarter earnings.
-
Zealand Pharma's drug reduces weight by 8.6% in early-stage study
-
Zealand Pharma says drug shows improvement in fatty liver disease patients
-
Madrigal's drug wins first US approval for fatty liver disease NASH as rivals circle
-
Ironwood's bowel disease drug meets main goal of late-stage study
-
Zealand, Boehringer's drug meets main weight-loss goal in mid-stage trial
-
Zealand Pharma expects to recover all deposits from SVB
Advertisement
Advertisement
Get updates on your preferred social platform
Follow us for the latest news, insider access to events and more.
